Saturday 17 October 2026
Export ALMS’s income statement to Excel — free account
Alumis Inc.
ALMS Healthcare Biotechnology
Alumis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $24.1 million. In the quarter to June 2026, revenue fell 37.7%, EPS fell 242.3% and free cash flow grew 23.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.12
0.19
−3.01%
Follow ALMS
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 7.46 | 2.76 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 13.53 | 12.44 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 109 | 170 | 224 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.11 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 24 | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | 100.00 | |||||
| EBT | — | — | — | — | — | — | — | (155) | (294) | (252) | |||||
| EBT margin, % | — | — | — | — | — | — | — | 0.00 | 0.00 | (1,047.34) | |||||
| Net income | — | — | — | — | — | — | — | (155) | (294) | (243) | |||||
| Depreciation | — | — | — | — | — | — | — | 1 | 3 | 3 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.28 | ||||
| Earnings | — | — | — | — | — | — | — | (72.08) | (10.38) | (2.86) | |||||
| Cash flow | — | — | — | — | — | — | — | (60.45) | (9.00) | (4.35) | |||||
| Capex | — | — | — | — | — | — | — | (2.09) | (0.06) | (0.01) | |||||
| Free cash flow | — | — | — | — | — | — | — | (62.54) | (9.06) | (4.35) | |||||
| Book value | — | — | — | — | — | — | — | (157.78) | 9.18 | 3.54 | |||||
| Shares, m | — | — | — | — | — | — | — | 2 | 28 | 85 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | — | 34.51 | |||||
| P/B | — | — | — | — | — | — | — | — | — | 2.75 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 21.68 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | (1.41) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (130) | (255) | (370) | ||||
| Capex | — | — | — | — | — | — | — | (4) | (2) | (1) | |||||
| Free cash flow | — | — | — | — | — | — | — | (134) | (257) | (370) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 32 | 255 | 245 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | (49) | (288) | (309) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | (339) | 260 | 301 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (136.66) | (64.63) | ||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | 743.43 | (86.68) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Alumis Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| JBIO Jade Biosciences, Inc. | $875.1M | — (loss-making) | — | — | n/m | −115.11% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MLTX MoonLake Immunotherapeutics | $873.2M | — (loss-making) | — | — | n/m | −1.89% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GLUE Monte Rosa Therapeutics, Inc. | $863.4M | — (loss-making) | — (loss-making) | −61.33% (below 0%: shrinking) | n/m | −34.11% (below 0%: shrinking) | 100.00% | (547.84%) | Compare |
| KURA Kura Oncology, Inc. | $862.9M | — (loss-making) | — (loss-making) | +36.54% (above 0%: growing) | n/m | −109.05% (below 0%: shrinking) | 98.84% | (349.77%) | Compare |
| ALMS Alumis Inc. | $842.4M | — (loss-making) | — (loss-making) | −37.66% (below 0%: shrinking) | n/m | +23.59% (above 0%: growing) | 100.00% | (8,956.38%) | |
| VSTM Verastem, Inc. | $835.9M | — (loss-making) | — (loss-making) | +1,775.43% (above 0%: growing) | n/m | −34.43% (below 0%: shrinking) | 89.92% | (81.62%) | Compare |
| CRVS Corvus Pharmaceuticals, Inc. | $828.6M | — (loss-making) | — | — | n/m | −171.31% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| AVBP ArriVent BioPharma, Inc. | $827.9M | — (loss-making) | — | — | n/m | −51.51% (below 0%: shrinking) | — | 0.00% | Compare |
| ARDX Ardelyx, Inc. | $814.9M | — (loss-making) | — (loss-making) | +23.77% (above 0%: growing) | n/m | +75.33% (above 0%: growing) | 95.24% | (10.28%) | Compare |
| Median of peers | $849.4M | — | — | +30.16% | — | −42.97% | 89.92% | (5.14%) |
Alumis Inc. (ALMS) key facts
- Alumis Inc. (ALMS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Alumis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $24.1 million.
- As of October 16, 2026, ALMS traded at $6.12, a market capitalization of $842.4 million.
- Return on equity was −86.7% and debt-to-equity 0.00.
- Its Altman Z-score is −1.43 (distress zone) for fiscal 2025.